Navigation Links
Cato Research and Cato BioVentures Announces the Opening of Houston, Texas, Office

Durham, NC (PRWEB) January 22, 2013

Cato Research (CATO), a full-service contract research organization (CRO) in its 25th year of global drug development success, and Cato BioVentures, CATO’s venture arm, proudly announce the opening of a new office in Houston, Texas.

CATO has managed many clinical trials at various research centers in Texas, in addition to supporting Texas-based companies and organizations. CATO has employed field-based clinical research personnel to manage trials both inside and outside the state. Recently, due in part to the CPRIT initiative, CATO has observed an upsurge of activity and need for life science industry services and expertise that CATO offers within the state of Texas. This initiative led to the establishment in 2012 of CATO’s first Texas office, located in Houston at the Greenway Building, 3200 S. W. Freeway, Suite 3300.

CATO has dedicated teams of specialists with many years of experience, one team of which is solely focused on oncology. These specialists work on many aspects of oncology product development, including preclinical, clinical trial development and operations, regulatory, regulatory filings, FDA interactions, and more. CATO’s frequent FDA interactions include experience with the FDA’s Division of Drug Oncology Products and Office of Hematology and Oncology Drug Products as well as experience in the design and successful completion of cancer clinical trials for a wide variety of technologies. These technologies include small molecules, biologics, cancer vaccines, devices, as well as drug, diagnostic, and combination products. CATO also has many years of experience working with early-stage start-up biotechnology companies as well as the larger and more established pharmaceutical companies.

CATO and Cato BioVentures operate as a global service provider without borders; thus, CATO seeks to utilize its dedicated personnel for each project on an experience-first basis, avoiding the limitations arising from geography. However, such is CATO’s commitment to Texas and understanding that Houston has become an internationally recognized biotechnology and pharmaceutical hub, that CATO has opened an office with a multidisciplinary team to sufficiently serve Texas sponsors.

“Recent funding initiatives offered by the state of Texas and by other prestigious organizations,” said Lynda Sutton, President and Cofounder of Cato Research, “are setting the foundations for Texas to emerge as a major biotech hub. We have witnessed this directly through our existing and increasing number of new sponsors who are establishing life science operations within the state. We see a major need and advantage for CATO to offer its regulatory and clinical services to local organizations through the support of a specialized, local team. Cato Research is committed to growing a significant presence for this purpose. In addition, the unique opportunity for Cato BioVentures to support the growth and success of products and technologies being developed within the region has given us added impetus to build a meaningful and functional representation. We are excited that CATO is a part of the biotech scene in Texas and is in a position to make a significant contribution to bringing new and innovative products that will result in improved outcomes and quality of life for cancer patients as well as for those with other major diseases. CATO has been involved in many cutting edge developments in its 25-year history, and we anticipate that collaborations and alliances within Texas will result in many more.”

About Cato Research
Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost-effectiveness. For more information about Cato Research, call 919-361-2286 or visit

About Cato BioVentures
Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization. For over 20 years, Cato BioVentures and
Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital™ in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry’s research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company’s business plan, then Cato BioVenture’s investment model can make a positive difference in the company’s overall success. For more information about Cato BioVentures, call 919-361-2286 or visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology:
(Date:10/26/2015)... 26, 2015  Delta ID Inc., a company focused ... and PC devices, announced its ActiveIRIS® technology powers the ... F-02H launched by NTT DOCOMO, INC in ... second smartphone to include iris recognition technology, after a ... F-04G in May 2015, world,s first smartphone to have ...
(Date:10/23/2015)... , October 23, 2015 ... announce a mobile plug and play integration of physiological ... tasks SensoMotoric Instruments (SMI) present a ... solutions for eye tracking and physiological data registration. It ... SMI Eye Tracking Glasses 2w and physiological signals ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):